| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTSO | Common Stock | Exercise of in-the-money or at-the-money derivative security | $15.9K | +15.9K | +12.66% | $1.00 | 141K | 17 Jan 2025 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTSO | Subscription Rights (right to buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -15.9K | -100% | $0.00 | 0 | 17 Jan 2025 | Common Stock | 15.9K | $1.00 | Direct | F1 |
| transaction | CTSO | Series A Right Warrants | Other | +15.9K | 15.9K | 17 Jan 2025 | Common Stock | 15.9K | Direct | F1, F3, F4 | ||||
| transaction | CTSO | Series B Right Warrants | Other | +15.9K | 15.9K | 17 Jan 2025 | Common Stock | 15.9K | Direct | F1, F5, F6 |
| Id | Content |
|---|---|
| F1 | On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879. The Rights Offering closed on January 10, 2025 (the "Closing Date"). |
| F2 | Includes (a) the following restricted stock units ("RSUs") which will vest upon a "Change of Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 56,094 shares of Common Stock owned by the reporting person. |
| F3 | The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00. |
| F4 | The Series A Right Warrants expire 45 calendar days following the Closing Date. |
| F5 | The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00. |
| F6 | The Series B Right Warrants expire 90 calendar days following the Closing Date. |